Pharmacokinetics and tolerability of oseltamivir combined with probenecid

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3013-3021

  Holodniy, Mark ^a,b,c   Penzak, Scott R ^d   Straight, Timothy M ^e   Davey, Richard T ^f   Lee, Kelvin K ^c,g   Goetz, Matthew Bidwell ^h,i   Raisch, Dennis W ^j   Cunningham, Francesca ^a   Lin, Emil T ^k   Olivo, Noemi ^c   Deyton, Lawrence R ^a,l  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b STANFORD UNIVERSITY   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e BROOKE ARMY MEDICAL CENTER   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g VA Cooperative Studies Program   (United States)

^h Greater Los Angeles Veterans Health Care System   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j University of New Mexico   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; PROBENECID;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BIOEQUIVALENCE; BLOOD PRESSURE FLUCTUATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG CLEARANCE; DRUG FEVER; DRUG TOLERABILITY; FEMALE; FLATULENCE; GASTROINTESTINAL DISEASE; GEOMETRY; HEMATURIA; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; LEUKOCYTE; MALE; MULTICENTER STUDY; NAUSEA; NECK PAIN; NORMAL HUMAN; OPEN STUDY; PHLEBITIS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SIDE EFFECT; STEADY STATE; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; URINALYSIS; VOMITING;

ADULT; AGED; ANTIVIRAL AGENTS; CHEMOPREVENTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OSELTAMIVIR; PROBENECID; TREATMENT OUTCOME;

EID: 50949094839     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00047-08     Document Type: Article

References (37)

1. Abe, M., J. Smith, A. Urae, J. Barrett, H. Kinoshita, and C. R. Rayner. 2006. Pharmacokinetics of oseltamivir in young and very elderly subjects. Ann. Pharmacother. 40:1724-1730.
2. Aruksakunwong, O., M. Malaisree, P. Decha, P. Sompornpisut, V. Parasuk, S. Pianwanit, and S. Hannongbua. 2007. On the lower susceptibility of oseltamivir to influenza neuraminidase subtype N1 than those in N2 and N9. Biophys. J. 92:798-807.
3. Bardsley-Elliot, A., and S. Noble. 1999. Oseltamivir. Drugs 58:851-860.
4. Chotpitayasunondh, T., K. Ungchusak, W. Hanshaoworakul, S. Chunsuthiwat, P. Sawanpanyalert, R. Kijphati, S. Lochindarat, P. Srisan, P. Suwan, Y. Osotthanakorn, T. Anantasetagoon, S. Kanjanawasri, S. Tanupattarachai, J. Weerakul, R. Chaiwirattana, M. Maneerattanaporn, R. Poolsavathitikool, K. Chokephaibulkit, A. Apisarnthanarak, and S. F. Dowell. 2005. Human disease from influenza A (H5N1), Thailand, 2004. Emerg. Infect. Dis. 11:201-209.
5. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
6. Cunningham, R. F., Z. H. Israili, and P. G. Dayton. 1981. Clinical pharmacokinetics of probenecid. Clin. Pharmacokinet. 6:135-151.
7. De Bony, F., M. Tod, R. Bidault, N. T. On, J. Posner, and P. Rolan. 2002. Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir. Antimicrob. Agents Chemother. 46:458-463.
8. de Jong, M. D., V. C. Bach, T. Q. Phan, M. H. Vo, T. T. Tran, B. H. Nguyen, M. Beld, T. P. Le, H. K. Truong, V. V. Nguyen, T. H. Tran, Q. H. Do, and J. Farrar. 2005. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N. Engl. J. Med. 352:686-691.
9. Doucette, K. E., and F. Y. Aoki. 2001. Oseltamivir: a clinical and pharmacological perspective. Expert Opin. Pharmacother. 2:1671-1683.
10. Emanuelsson, B. M., B. Beermann, and L. K. Paalzow. 1987. Non-linear elimination and protein binding of probenecid. Eur. J. Clin. Pharmacol. 32:395-401.
11. EMEA. 2007, posting date. European public assessment report: Tamiflu, 18 December 2007. EMEA, London, United Kingdom. http://www.emea .europa.eu/humandocs/Human/EPAR/tamiflu/tamiflu.htm.
12. Govorkova, E. A., I. A. Leneva, O. G. Goloubeva, K. Bush, and R. G. Webster. 2001. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. 45:2723-2732.
13. Hill, G., T. Cihlar, C. Oo, E. S. Ho, K. Prior, H. Wiltshire, J. Barrett, B. Liu, and P. Ward. 2002. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion - correlation of in vivo and in vitro studies. Drug Metab. Dispos. 30:13-19.
14. Kati, W. M., A. S. Saldivar, F. Mohamadi, H. L. Sham, W. G. Laver, and W. E. Kohlbrenner. 1998. GS4071 is a slow-binding inhibitor of influenza neuraminidase from both A and B strains. Biochem. Biophys. Res. Commun. 244:408-413.
15. Kim, K. A., S. O. Oh, P. W. Park, and J. Y. Park. 2005. Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. Eur. J. Clin. Pharmacol. 61:275-280.
16. Koopmans, M., B. Wilbrink, M. Conyn, G. Natrop, H. van der Nat, H. Vennema, A. Meijer, J. van Steenbergen, R. Fouchier, A. Osterhaus, and A. Bosman. 2004. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in The Netherlands. Lancet 363:587-593.
17. Krogsgaard, M. R., B. A. Hansen, T. Slotsbjerg, and P. Jensen. 1994. Should probenecid be used to reduce the dicloxacillin dosage in orthopaedic infections? A study of the dicloxacillin-saving effect of probenecid. Pharmacol. Toxicol. 74:181-184.
18. Leneva, I. A., N. Roberts, E. A. Govorkova, O. G. Goloubeva, and R. G. Webster. 2000. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antivir. Res. 48:101-115.
19. Liem, N. T., and W. Lim. 2005. Lack of H5N1 avian influenza transmission to hospital employees, Hanoi, 2004. Emerg. Infect. Dis. 11:210-215.
20. Lindegardh, N., G. R. Davies, T. T. Hien, J. Farrar, P. Singhasivanon, N. P. Day, and N. J. White. 2007. Importance of collection tube during clinical studies of oseltamivir. Antimicrob. Agents Chemother. 51:1835-1836.
21. Lindegardh, N., G. R. Davies, T. H. Tran, J. Farrar, P. Singhasivanon, N. P. Day, and N. J. White. 2006. Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases. Antimicrob. Agents Chemother. 50: 3197-3199.
22. Macdonald, J. I., S. M. Wallace, R. J. Herman, and R. K. Verbeeck. 1995. Effect of probenecid on the formation and elimination kinetics of the sulphate and glucuronide conjugates of diflunisal. Eur. J. Clin. Pharmacol. 47:519-523.
23. Markowitz, J. S., C. L. Devane, H. L. Liston, D. W. Boulton, and S. C. Risch. 2002. The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers. Clin. Pharmacol. Ther. 71:30-38.
24. Mendel, D. B., C. Y. Tai, P. A. Escarpe, W. Li, R. W. Sidwell, J. H. Huffman, C. Sweet, K. J. Jakeman, J. Merson, S. A. Lacy, W. Lew, M. A. Williams, L. Zhang, M. S. Chen, N. Bischofberger, and C. U. Kim. 1998. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother. 42:640-646.
25. Monto, A. S., J. Rotthoff, E. Teich, M. L. Herlocher, R. Truscon, H. L. Yen, S. Elias, and S. E. Ohmit. 2004. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin. Infect. Dis. 39:459-464.
26. Oo, C., J. Barrett, G. Hill, J. Mann, A. Dorr, R. Dutkowski, and P. Ward. 2001. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatr. Drugs 3:229-236.
27. Osterholm, M. T. 2005. Preparing for the next pandemic. N. Engl. J. Med. 352:1839-1842.
28. Schentag, J. J., G. Hill, T. Chu, and C. R. Rayner. 2007. Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J. Clin. Pharmacol. 47:689-696.
29. Selen, A., G. L. Amidon, and P. G. Welling. 1982. Pharmacokinetics of probenecid following oral doses to human volunteers. J. Pharm. Sci. 71: 1238-1242.
30. Taubenberger, J. K., A. H. Reid, R. M. Lourens, R. Wang, G. Jin, and T. G. Fanning. 2005. Characterization of the 1918 influenza virus polymerase genes. Nature 437:889-893.
31. Tumpey, T. M., C. F. Basler, P. V. Aguilar, H. Zeng, A. Solorzano, D. E. Swayne, N. J. Cox, J. M. Katz, J. K. Taubenberger, P. Palese, and A. Garcia-Sastre. 2005. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310:77-80.
32. Tweed, S. A., D. M. Skowroski, S. T. David, A. Larder, M. Petric, W. Lees, Y. Li, J. Katz, M. Krajden, R. Tellier, C. Halpert, M. Hirst, C. Astell, D. Lawrence, and A. Mak. 2004. Human illness from avian influenza H7N3, British Columbia. Emerg. Infect. Dis. 10:2196-2199.
33. Ungchusak, K., P. Auewarakul, S. F. Dowell, R. Kitphati, W. Auwanit, P. Puthavathana, M. Uiprasertkul, K. Boonnak, C. Pittayawonganon, N. J. Cox, S. R. Zaki, P. Thawatsupha, M. Chittaganpitch, R. Khontong, J. M. Simmerman, and S. Chunsutthiwat. 2005. Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med. 352:333-340.
34. U.S. Food and Drug Administration, CDER. 2001. Guidance for industry: statistical approaches to establishing bioequivalence. U.S. Food and Drug Administration, Rockville, MD.
35. max-finding study. Pharm. Weekbl. Sci. 14:325-331.
36. World Health Organization. 2006, posting date. Avian influenza ("bird flu") - Fact Sheet. World Health Organization, Geneva, Switzerland.
37. World Health Organization. 2008, posting date. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. World Health Organization, Geneva, Switzerland.